O-POINTED SIGNED
Osteoarthritis patient cohorts in the dish - personalised cellular drug development tools for osteoarthritis precision medicine
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0O-POINTED project word cloud
Explore the words cloud of the O-POINTED project. It provides you a very rough idea of what is the project "O-POINTED" about.
Project "O-POINTED" data sheet
The following table provides information about the project.
| Coordinator |
InSCREENeX GmbH
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-06-01 to 2019-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | InSCREENeX GmbH | DE (BRAUNSCHWEIG) | coordinator | 50˙000.00 |
Map
Project objective
Osteoarthritis is the fastest growing cause of disability worldwide. Still, there is currently no drug available that targets the underlying pathophysiology of osteoarthritis. Clinical trials testing disease-modifying drug candidates consistently fail. This is because osteoarthritis is a complex disease and currently used drug development tools completely disregard patient variability. Consequently, such non-personalised drugs fail to reach high enough response rates in highly variable osteoarthritis patient populations. O-POINTED is the first tool to enable pharma and biotech companies to personalise the osteoarthritis drug development process. O-POINTED is a cellular test system based on personalised and expandable cell lines generated from a cohort of more than 50 osteoarthritis patients. It represents osteoarthritis patient variability including all the main disease phenotypes (bone-, cartilage-, synovium-driven). Compared to conventional test systems, it is easier to use and more relevant, with the unique benefit of representing osteoarthritis patient variability. The combined O-POINTED business model includes a double one-off revenue (product plus consumables) and recurring revenue (milestone-based payments). We estimate that O-POINTED will create €2.9 million revenue and 15 new jobs, 3 years after commercial launch. We have a key customer already testing a minimal viable product of O-POINTED and seek Phase 1 support to evaluate the feasibility of scaling up to a European and Global dimension.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "O-POINTED" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "O-POINTED" are provided by the European Opendata Portal: CORDIS opendata.